Skip to main content
. 2015 May 8;6(26):22996–23007. doi: 10.18632/oncotarget.4035

Figure 6. FXYD3 expression in the primary tumors of patients with mCRC and the related PFS.

Figure 6

A. Two different tumor samples with different cytoplasmic staining intensity for FXYD3 (weak vs strong). B. Two patient sub-groups based on FXYD3 expression. Left: the number of patients per staining category. The majority of the samples showed strong staining. Right: Kaplan-Meier survival analysis comparing patients with weak and strong staining. A significant association between PFS and FXYD3 was observed.